HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Oral PCSK9 inhibitor AZD0780 cut LDL at least 30% in phase 1, 78% with rosuvastatin

Gokhan Can · Jun 28, 2024 · ♥ 17 reactions · 1 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panel
AI summary & key facts

A phase 1 trial presented at EAS 2024 found AZD0780, the first oral small-molecule PCSK9 inhibitor, cut LDL by at least 30% in 35 participants, and a subanalysis suggested a 78% reduction with rosuvastatin. Specialists question the early data.

A preliminary phase 1 trial of AZD0780, the first oral small molecule PCSK9 inhibitor, has shown promising results in lowering LDL cholesterol levels. The study, presented at the European Atherosclerosis Society (EAS) 2024 conference, found that AZD0780 reduced LDL cholesterol by at least 30% in 35 participants with elevated LDL. A subanalysis within the trial suggested a potential synergistic effect when AZD0780 was combined with the statin rosuvastatin, resulting in a 78% reduction in LDL cholesterol levels. Rick Vega, Director of Research at AstraZeneca, stated that these findings indicate a fixed-dose combination of AZD0780 with a statin could be an attractive first-line treatment option.

MedscapeFirst Oral PCSK9 Shows Promise Lowering CholesterolAZD0780 — the first oral PCSK9 inhibitor — is lowering LDL cholesterol levels, report phase 1 trial investigators, but specialists are questioning the early findings.medscape.com

Research cited

#cholesterol#pcsk9#rosuvastatin#statins#atherosclerosis
← newer: Optimal diets vary: Mediterranean first, with individualizedolder: Do glucose spikes cause heart disease? Plausible mechanisms, →